Research Analysts Issue Forecasts for VRTX FY2026 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at Erste Group Bank raised their FY2026 earnings per share estimates for Vertex Pharmaceuticals in a note issued to investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now expects that the pharmaceutical company will earn $16.93 per share for the year, up from their previous forecast of $16.91. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $17.01 per share. Erste Group Bank also issued estimates for Vertex Pharmaceuticals’ FY2027 earnings at $18.97 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business had revenue of $2.99 billion for the quarter, compared to analyst estimates of $2.99 billion. During the same period in the previous year, the firm earned $4.06 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year.

A number of other analysts have also recently issued reports on the stock. Weiss Ratings cut shares of Vertex Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Royal Bank Of Canada raised their price objective on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Truist Financial lifted their price target on Vertex Pharmaceuticals from $542.00 to $560.00 and gave the stock a “buy” rating in a report on Monday. Barclays boosted their price target on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Morgan Stanley increased their price objective on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Twenty-one analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $559.61.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $486.03 on Friday. Vertex Pharmaceuticals has a one year low of $362.50 and a one year high of $533.67. The stock has a market cap of $123.35 billion, a price-to-earnings ratio of 28.83, a price-to-earnings-growth ratio of 2.07 and a beta of 0.29. The company has a fifty day moving average price of $461.42 and a two-hundred day moving average price of $458.82.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Joy Liu sold 1,104 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $425.02, for a total transaction of $469,222.08. Following the transaction, the executive vice president owned 20,729 shares in the company, valued at $8,810,239.58. This trade represents a 5.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the transaction, the executive vice president directly owned 45,321 shares of the company’s stock, valued at $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,874 shares of company stock valued at $8,707,966 in the last quarter. Corporate insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Bangor Savings Bank grew its stake in Vertex Pharmaceuticals by 0.4% during the second quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock worth $2,220,000 after buying an additional 20 shares in the last quarter. Earned Wealth Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 3.3% during the 4th quarter. Earned Wealth Advisors LLC now owns 650 shares of the pharmaceutical company’s stock worth $295,000 after acquiring an additional 21 shares in the last quarter. Confluence Wealth Services Inc. increased its stake in Vertex Pharmaceuticals by 4.0% in the fourth quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company’s stock valued at $247,000 after acquiring an additional 21 shares during the last quarter. Trust Point Inc. increased its stake in Vertex Pharmaceuticals by 2.7% in the second quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock valued at $394,000 after acquiring an additional 21 shares during the last quarter. Finally, Williams Jones Wealth Management LLC. raised its position in Vertex Pharmaceuticals by 1.9% during the fourth quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock valued at $524,000 after purchasing an additional 21 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.